Aligos Therapeutics, Inc. (ALGS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-11

Key Insights

Nikhil Aneja, the Principal Accounting Officer of Aligos Therapeutics, Inc., acquired 9,450 stock options with an exercise price of $7.03 on March 9, 2026, indicating insider confidence in the company's future.
The stock options vest over a 4-year period, suggesting a long-term commitment from the reporting person to the company's success.
This filing provides transparency into insider trading activity, which can be an important signal for investors when evaluating the company's prospects.

Want the newest filings?

This analysis covers the filing from 2026-03-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-11

The reporting person, Julian A. Symons, was granted 23,310 stock options to purchase common stock of Aligos Therapeutics, Inc. on March 9, 2026, with a strike price of $7.03 per share and a 10-year expiration.
The options will vest in 48 equal monthly installments, with 100% vesting on the 4th anniversary of the grant date, subject to the reporting person's continued service.
This stock option grant suggests the company is providing long-term equity incentives to the Chief Scientific Officer to align his interests with shareholders and incentivize his continued leadership.

Other reports for Aligos Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.